Hefei Lifeon Pharmaceutical Co., Ltd.

Equities

003020

CNE100004BD9

Pharmaceuticals

End-of-day quote Shenzhen S.E. 03:30:00 23/05/2024 am IST 5-day change 1st Jan Change
24.76 CNY +2.65% Intraday chart for Hefei Lifeon Pharmaceutical Co., Ltd. +3.82% -12.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lifeon Pharmaceutical's Unit Gets Marketing Authorization for Loxoprofen Sodium Oral Solution MT
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lifeon Pharma’s Diabetes Drugs Pass China Consistency Evaluation MT
Certain A Shares of Hefei Lifeon Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2023. CI
Lifeon Pharmaceutical Gets Chinese Drug Regulator's Nod to Market Doxazosin Mesylate MT
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Election of Shi Jing as an Independent Director CI
Hefei Lifeon Pharmaceutical Co., Ltd., Hefei Xinchen Enterprise Management Consulting Co., Ltd., Li Chao and Deng Xiaojuan agreed to acquire Hefei Noratech Pharmaceuticals Co., Ltd. from Roaring Success Ltd and Hefei Xinchen Enterprise Management Consulting Co., Ltd. for CNY 72 million. CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hefei Lifeon Pharmaceutical Co., Ltd.(XSEC:003020) added to S&P Global BMI Index CI
Hefei Lifeon Pharmaceutical Co., Ltd. signed equity transfer agreement to acquire 51% stake in Anhui Joyfar Pharmaceutical Co. Ltd. from Beijing Huixu Jintong Investment Center (Limited Partnership), Beijing Huixu Jintai Investment Center (Limited Partnership), Gong Tonglin, Shen Jun, Zhao Shoutian and Ouyang Hanlin for approximately CNY 220 million. CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hefei Lifeon Pharmaceutical Co., Ltd. Declares Cash Dividend on A Shares for 2022, Payable on May 24, 2023 CI
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023 CI
Hefei Lifeon Pharmaceutical Co., Ltd. Proposes Final Dividend for 2022 CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hefei Lifeon Pharma’s Blood Pressure Drug Joins Bid For Inclusion in China’s Drug Procurement Program MT
Worldunion Group CFO Resigns; Successor Named MT
Anhui Lifeon Pharmaceutical Co., Ltd. announced that it expects to receive CNY 113 million in funding from Hefei Lifeon Pharmaceutical Co., Ltd. CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hefei Lifeon Pharmaceutical Co., Ltd. Announces Board Appointments CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Pingtan Wenzhou Ruiji Investment Partnership Enterprise and Zhuzhou Wenzhou Junzhe Venture Capital Partnership Enterprise (L.P.) managed by Shanghai Wenzhou Investment Management Co., Ltd. completed the acquisition of 4.94% stake in Minova Pharma from Hefei Lifeon Pharmaceutical Co., Ltd. for approximately CNY 32.1 million. CI
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021R CI
Chart Hefei Lifeon Pharmaceutical Co., Ltd.
More charts
Hefei Lifeon Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical preparations and active pharmaceutical ingredients (APIs). The Company is also engaged in the wholesale and retailing of pharmaceuticals and medical devices. The Company's main products involve cardiovascular drugs, digestive system drugs and skin topical drugs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
24.76
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 003020 Stock
  4. News Hefei Lifeon Pharmaceutical Co., Ltd.
  5. Hefei Lifeon Pharma’s Blood Pressure Drug Joins Bid For Inclusion in China’s Drug Procurement Program